![](/imgs/covers/cr_cover.jpg)
|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 6, No. 4, 2010, pp. 557-559
|
Bioline Code: cr10137
Full paper language: English
Document type: Case Report
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 6, No. 4, 2010, pp. 557-559
en |
Capecitabine-related intracranial hypotension syndrome mimicking dural metastasis in a breast cancer patient: Case report and review of the literature
Cosar-Alas, Rusen; Alas, Aykan; Ozen, Alaattin; Denizli, Bengu; Saynak, Mert; Uzunoglu, Sernaz; Aydogdu, Nurettin; Karagol, Hakan; Uzal, Cem & Kocak, Zafer
Abstract
Spontaneous intracranial hypotension (SICH) is an entity, which is secondary to iatrogenic manipulation and breaching of dura. Postural headache in patients should be suspected, cranial magnetic resonance imaging (MRI) is essential for precise diagnosis. Hallmark of MRI is regular shape of pachymeningeal gadolinium enhancement and subdural effusion. It may mimic central nervous system (CNS) metastasis. Prevention of such cases from receiving cranial radiotherapy by misinterpretation of the gadolinium enhancement as CNS metastasis is an important issue. Capecitabine is an antineoplastic agent, of which metabolites can cross blood-brain barrier in CNS via epithelial tissue. It may cause decrease in CSF production. SICH might be the clinical reflection of this decrease in CSF production. Review of the English literature revealed limited data because of the very little experience with oncologic patients suffering from intracranial hypotension. We report a case of spontaneous intracranial hypotension during capecitabine treatment. Patient was completely well following drug discontinuation and supportive treatment.
Keywords
Capecitabine, mimicking dural metastasis, orthostatic headache, spontaneous intracranial hypotension syndrome
|
|
© Copyright 2010 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|